Voyager Therapeutics (NASDAQ: VYGR) — Perfil da empresa, notícias e dados financeiros
Voyager Therapeutics develops gene therapies for severe neurological diseases, focusing on innovative viral vector platforms for treatment delivery.
Voyager Therapeutics
Voyager Therapeutics (NASDAQ:VYGR) is a dynamic biotechnology firm engaged in developing gene therapies that aim to provide life-changing treatments for severe neurological diseases. This endeavor involves a focus on creating innovative viral vector platforms to deliver genetic material directly into cells to correct or counteract diseases like Parkinson's, Huntington's, and ALS, among others. By pushing the boundaries of gene therapy, Voyager Therapeutics seeks not only to expand scientific understanding but also to translate groundbreaking research into therapies that can profoundly impact patient care and quality of life. The company's objectives are deeply rooted in a commitment to innovation, patient health, and developing sustainable treatments that address some of the most challenging medical conditions faced today.
Resumo
Operações
Produtos e/ou serviços de Voyager Therapeutics
- Gene therapy programs targeting Parkinson's disease, using adeno-associated virus vectors to deliver therapeutic genes directly to the brain.
- Huntington's disease gene therapy project, aimed at reducing the production of mutant huntingtin protein.
- ALS gene therapy development, focusing on silencing genes responsible for ALS.
- Friedreich's Ataxia targeted gene therapy, aiming to increase frataxin protein expression.
- Technology platform for the development of next-generation AAV capsids, enhancing gene therapy delivery and specificity.
- Collaborations with pharmaceutical companies to co-develop gene therapies for severe neurological diseases.
equipe executiva do Voyager Therapeutics
- Alfred W. Sandrock Jr.President, CEO & Director
- Robin SwartzPrincipal Financial Officer, Treasurer, Chief Business Officer & COO
- Krystof BankiewiczFounder
- Mark A. KayFounder
- Amy QuinlanPrincipal Accounting Officer
- Todd CarterChief Scientific Officer
- Trista MorrisonChief Corporate Affairs Officer & Chief of Staff to the CEO
- Mathieu NonnenmacherVice President of Gene Therapy
- Mihalis KariolisVice President of Non-Viral Therapeutics
Últimas notícias sobre a Voyager Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Voyager Therapeutics, em USD.
- Cap. de mercado
- 106,6 mi
- Receita (TTM)
- 34,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.8
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 40,4 mi | -131,8 mi | -119,7 mi | |
| 80 mi | -83,3 mi | -65 mi | |
| 250 mi | 122 mi | 132,3 mi | |
| 40,9 mi | -50,8 mi | -46,4 mi |